威麦宁胶囊联合奥希替尼治疗EGFR T790M突变晚期肺腺癌的临床疗效

Clinical efficacy of Weimaining capsule combined with osimertinib in the treatment of EGFR T 790M mutant advanced lung adenocarcinoma

目的观察威麦宁胶囊联合奥希替尼治疗表皮生长因子受体(EGFR)T790M突变晚期肺腺癌的临床疗效.方法60例EGFR T790M突变晚期肺腺癌患者随机均分为两组,对照组采用奥希替尼80 mg,1次/天;观察组在奥希替尼治疗的基础上加用威麦宁胶囊6~8粒/次,3次/天.比较两组临床疗效和不良反应发生情况.结果治疗1个月后,观察组和对照组总有效率相仿(20.00%vs.16.67%)(P>0.05),但观察组疾病控制率高于对照组(73.33%vs.46.67%)(P<0.05),疾病无进展生存期长于对照组[(11.40±0.20)个月vs.(10.67±0.28)个月](P<0.05).两组均未出现药物相关的心电图Q-T间期延长和间质性肺炎,且骨髓抑制、腹泻、皮疹和口腔炎等不良反应发生率无统计学差异(P>0.05).结论威麦宁胶囊联合奥希替尼能够进一步提高EGFR T790M突变晚期肺腺癌患者的疾病控制率,延长患者疾病无进展生存期.

Objective To observe the clinical efficacy of Weimaining capsule combined with osimertinib in the treatment of epidermal growth factor receptor(EGFR)T790M mutant advanced lung adenocarcinoma.Methods A total of 60 patients with EGFR T790M mutation advanced lung adenocarcinoma were equally randomized into two groups.Group A was treated with osimertinib 80 mg,once a day.Group B was treated with osimertinib and w eimaining capsules 6-8 capsules once,3 times a day,The clinical efficacy and adverse responses were compared between the two groups.Results After 1 month of treatment,the overall effectiveness rate of group B was similar to that of group A(20,00%vs,16.67%)(P>0.05),but the disease control rate of group B was higher than that of group A(73.33%vs,46.67%)(P<0.05)and the progression-free survival time of group B was longer than that of group A[(11.40±0.20)months vs.(10.67±0.28)months](P<0.05).There were no drug related ECG Q-T interval prolongation and interstitial pneumonia in two groups.The incidence rates of bone marrow suppression,diarrhea,rash,and stomatitis were not significantly different between the two groups(P>0.05).Conclusion W eimaining capsules combined with osimertinib can further improve the disease control rate and prolong the disease progression-free survival of the patients with EGFR T790M mutation advanced lung adenocarcinoma,